Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELU) EBT (2020 - 2025)

Celularity (CELU) has disclosed EBT for 6 consecutive years, with -$23.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 43.35% to -$23.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$80.6 million, a 130.14% decrease, with the full-year FY2024 number at -$57.9 million, up 70.51% from a year prior.
  • EBT was -$23.1 million for Q3 2025 at Celularity, up from -$24.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $49.9 million in Q3 2021 to a low of -$93.9 million in Q3 2023.
  • A 5-year average of -$21.4 million and a median of -$19.8 million in 2025 define the central range for EBT.
  • Peak YoY movement for EBT: surged 708.13% in 2022, then crashed 2063.11% in 2023.
  • Celularity's EBT stood at -$4.0 million in 2021, then soared by 708.13% to $24.4 million in 2022, then plummeted by 60.91% to $9.6 million in 2023, then crashed by 239.09% to -$13.3 million in 2024, then crashed by 73.6% to -$23.1 million in 2025.
  • Per Business Quant, the three most recent readings for CELU's EBT are -$23.1 million (Q3 2025), -$24.5 million (Q2 2025), and -$19.8 million (Q1 2025).